INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026
INOVIO (NASDAQ: INO) will release its third quarter 2026 financial results after the market close on November 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
INOVIO (NASDAQ: INO) will release its third quarter 2026 financial results after the market close on November 10, 2026. A live conference call and webcast will follow at 4:30 p.m. ET to discuss the results and provide a general business update. The webcast will be available on the company’s website, with a replay available for 90 days following the event.
Details
Market move: INO +3.70% vs previous close. Q3 2026 earnings report
On Nov 2, the day this news came out, the latest delayed price for INO is 3.70% above the previous close. Our momentum scanner has recorded 63 alerts for this stock so far that day. The latest delayed price is $1.96. Relative volume is exceptionally heavy at 71.3x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Reporting period
- Q3 2026
- Financial results to be reported
- Results release date
- November 10, 2026
- After market close
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast of the call will be available on the company's website at https://ir.inovio.com/events-and-presentations. The webcast will be archived and available for replay for 90 days following the event.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing innovative DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of DNA medicines that enable the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com
Contacts
Media: Josephine Galatioto - ICR Healthcare, inoviopr@icrhealthcare.com
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, peter.vozzo@icrhealthcare.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-report-third-quarter-2026-financial-results-on-november-10-2026-302926888.html
SOURCE INOVIO Pharmaceuticals, Inc.